Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2021
|
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
amivantamab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rybrevant
|
| gptkbp:indication |
gptkb:non-small_cell_lung_cancer
EGFR exon 20 insertion mutations |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Janssen_Biotech
|
| gptkbp:mechanismOfAction |
EGFR-MET bispecific antibody
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
edema
rash infusion-related reactions paronychia hypoalbuminemia |
| gptkbp:status |
FDA approved
|
| gptkbp:target |
gptkb:EGFR
gptkb:MET |
| gptkbp:bfsParent |
gptkb:Amivantamab
|
| gptkbp:bfsLayer |
7
|